RATIONALE: In regenerative therapy for ischemic heart disease, use of both autologous and allogeneic stem cells has been investigated. Autologous cell can be applied without immunosuppression, but availability is restricted, and cells have been exposed to risk factors and aging. Allogeneic cell therapy enables preoperative production of potent cell lines and immediate availability of cell products, allowing off-the-shelf therapy. It is unknown which cell source is preferred with regard to improving cardiac function. OBJECTIVE: We performed a meta-analysis of preclinical data of cell therapy for ischemic heart disease. METHODS AND RESULTS: We conducted a systematic literature search to identify publications describing controlled preclinical trials of unmodified stem cell therapy in large animal models of myocardial ischemia. Data from 82 studies involving 1415 animals showed a significant improvement in mean left ventricular ejection fraction in treated compared with control animals (8.3%, 95% confidence interval, 7.1-9.5; P<0.001). Meta-regression revealed a similar difference in left ventricular ejection fraction in autologous (8.8%, 95% confidence interval, 7.3-10.3; n=981) and allogeneic (7.3%, 95% confidence interval, 4.4-10.2, n=331; P=0.3) cell therapies. CONCLUSIONS: Autologous and allogeneic cell therapy for ischemic heart disease show a similar improvement in left ventricular ejection fraction in large animal models of myocardial ischemia, compared with placebo. These results are important for the design of future clinical trials.
RATIONALE: In regenerative therapy for ischemic heart disease, use of both autologous and allogeneic stem cells has been investigated. Autologous cell can be applied without immunosuppression, but availability is restricted, and cells have been exposed to risk factors and aging. Allogeneic cell therapy enables preoperative production of potent cell lines and immediate availability of cell products, allowing off-the-shelf therapy. It is unknown which cell source is preferred with regard to improving cardiac function. OBJECTIVE: We performed a meta-analysis of preclinical data of cell therapy for ischemic heart disease. METHODS AND RESULTS: We conducted a systematic literature search to identify publications describing controlled preclinical trials of unmodified stem cell therapy in large animal models of myocardial ischemia. Data from 82 studies involving 1415 animals showed a significant improvement in mean left ventricular ejection fraction in treated compared with control animals (8.3%, 95% confidence interval, 7.1-9.5; P<0.001). Meta-regression revealed a similar difference in left ventricular ejection fraction in autologous (8.8%, 95% confidence interval, 7.3-10.3; n=981) and allogeneic (7.3%, 95% confidence interval, 4.4-10.2, n=331; P=0.3) cell therapies. CONCLUSIONS: Autologous and allogeneic cell therapy for ischemic heart disease show a similar improvement in left ventricular ejection fraction in large animal models of myocardial ischemia, compared with placebo. These results are important for the design of future clinical trials.
Authors: Elena Cambria; Julia Steiger; Julia Günter; Annina Bopp; Petra Wolint; Simon P Hoerstrup; Maximilian Y Emmert Journal: Transfus Med Hemother Date: 2016-07-26 Impact factor: 3.747
Authors: Makoto Natsumeda; Victoria Florea; Angela C Rieger; Bryon A Tompkins; Monisha N Banerjee; Samuel Golpanian; Julia Fritsch; Ana Marie Landin; Nilesh D Kashikar; Vasileios Karantalis; Viky Y Loescher; Kostas E Hatzistergos; Luiza Bagno; Cristina Sanina; Muzammil Mushtaq; Jose Rodriguez; Marcos Rosado; Ariel Wolf; Kevin Collon; Louis Vincent; Anthony J Kanelidis; Ivonne H Schulman; Raul Mitrani; Alan W Heldman; Wayne Balkan; Joshua M Hare Journal: J Am Coll Cardiol Date: 2017-11-14 Impact factor: 24.094
Authors: Rosalinda Madonna; Linda W Van Laake; Hans Erik Botker; Sean M Davidson; Raffaele De Caterina; Felix B Engel; Thomas Eschenhagen; Francesco Fernandez-Aviles; Derek J Hausenloy; Jean-Sebastien Hulot; Sandrine Lecour; Jonathan Leor; Philippe Menasché; Maurizio Pesce; Cinzia Perrino; Fabrice Prunier; Sophie Van Linthout; Kirsti Ytrehus; Wolfram-Hubertus Zimmermann; Peter Ferdinandy; Joost P G Sluijter Journal: Cardiovasc Res Date: 2019-03-01 Impact factor: 10.787
Authors: Geoffrey de Couto; Romain Gallet; Linda Cambier; Ervin Jaghatspanyan; Nupur Makkar; James Frederick Dawkins; Benjamin P Berman; Eduardo Marbán Journal: Circulation Date: 2017-04-14 Impact factor: 29.690
Authors: Rhys J P Skelton; Suhail Khoja; Shone Almeida; Stanislas Rapacchi; Fei Han; James Engel; Peng Zhao; Peng Hu; Edouard G Stanley; Andrew G Elefanty; Murray Kwon; David A Elliott; Reza Ardehali Journal: Stem Cells Transl Med Date: 2015-11-18 Impact factor: 6.940
Authors: Rosalinda Madonna; Linda W Van Laake; Sean M Davidson; Felix B Engel; Derek J Hausenloy; Sandrine Lecour; Jonathan Leor; Cinzia Perrino; Rainer Schulz; Kirsti Ytrehus; Ulf Landmesser; Christine L Mummery; Stefan Janssens; James Willerson; Thomas Eschenhagen; Péter Ferdinandy; Joost P G Sluijter Journal: Eur Heart J Date: 2016-04-07 Impact factor: 29.983